Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model

Zheng,Yong‑Fa; Ge,Wei; Xu,Hui‑Lin; Cao,De‑Dong; Liu,Liang; Ming,Ping‑Po; Li,Chang‑Hu; Xu,Xi‑Ming; Tao,Wei‑Ping; Tao,Ze‑Zhang

doi:10.3892/ol.2015.3679

Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model

Authors:
- Yong‑Fa Zheng
- Wei Ge
- Hui‑Lin Xu
- De‑Dong Cao
- Liang Liu
- Ping‑Po Ming
- Chang‑Hu Li
- Xi‑Ming Xu
- Wei‑Ping Tao
- Ze‑Zhang Tao
View Affiliations

Affiliations: Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Otolaryngology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: September 7, 2015 https://doi.org/10.3892/ol.2015.3679
Pages: 3067-3072

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a leading cause of morbidity and mortality. Previous studies have identified that an improvement in treatment efficacy was achieved using Endostar; however, the role of Endostar in lung cancer remains poorly understood. The present study investigated whether the enhanced antitumor effects of Endostar in combination with radiation involved changes in the metabolism and microenvironment in non‑small cell lung cancer. A Lewis lung carcinoma mouse model was used, including the control, Endostar (ES), radiotherapy (RT) and Endostar plus radiotherapy (ES + RT) groups. The tumor inhibition rates and growth were described based on changes in tumor volume. In addition, ultraviolet enzymatic analysis was performed to determine the lactate level and reverse transcription‑polymerase chain reaction was used to measure the mRNA expression of lactate dehydrogenase (LDH). A Meph‑3 pH meter was used to detect the ranges of tumor interstitial tissue pH, and immunohistochemical analysis was adopted to examine hypoxia within the tumor microenvironment. The tumor inhibition rate of the ES + RT group was significantly higher compared with the other three groups (P<0.05). Following treatment, the lactate levels decreased in all three treatment groups compared with the control, particularly in the ES + RT group (P<0.05). Reduced LDH expression and hypoxic fraction in the tumor microenvironment were also observed in the ES + RT group (P<0.05). Furthermore, changes from acidic to alkaline pH in the tumor microenvironment were detected in the ES + RT group. The present study suggested that Endostar is involved in the regulation of metabolism and tumor microenvironment hypoxia, which may be responsible for the enhanced antitumor effect of Endostar in combination with radiotherapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Tiwari RC, Murray T, Ghafoor A, et al: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
3	No authors listed: Cancer facts and figures 2004. American Cancer Society. Atlanta, GA: 2004.
4	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kobayashi K and Hagiwara K: Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol. 8:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
6	Bria E, Bonomi M, Pilotto S, et al: Clinical meta-analyses of targeted therapies in adenocarcinoma. Target Oncol. 8:35–45. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ge W, Cao DD, Wang HM, Jie FF, Zheng YF and Chen Y: Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev. 12:2705–2711. 2011.PubMed/NCBI
8	Du Y, Peyser ND and Grandis JR: Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther. 142:88–98. 2014. View Article : Google Scholar : PubMed/NCBI
9	Koh PK, Faivre-Finn C, Blackhall FH and De Ruysscher D: Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev. 38:626–640. 2012. View Article : Google Scholar : PubMed/NCBI
10	Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 312:594–607. 2006. View Article : Google Scholar : PubMed/NCBI
11	O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
12	Meijer TW, Kaanders JH, Span PN and Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Ge W, Hu K, et al: Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep. 39:89–95. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ge W, Zheng Y, Zhang L, et al: Endostar enhances the radioresponse on Lewis lung carcinoma by regulating HIF-1α. Biomedical Engineering and Informatics (BMEI), 2011. 4th International Conference. Ding YS, Peng YH, Shi R, et al: 3:(IEEE, Shanghai). 1486–1490. 2011. View Article : Google Scholar
15	Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 9:1084–1101. 2009. View Article : Google Scholar : PubMed/NCBI
16	Winum JY, Rami M, Scozzafava A, Montero JL and Supuran C: Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev. 28:445–463. 2008. View Article : Google Scholar : PubMed/NCBI
17	Yokota H, Guo J, Matoba M, et al: Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging. 25:992–999. 2007. View Article : Google Scholar : PubMed/NCBI
18	Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al: Ketones and lactate ‘fuel’ tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 9:3506–3514. 2010. View Article : Google Scholar : PubMed/NCBI
19	Goetze K, Walenta S, Ksiazkiewicz M, et al: Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol. 39:453–463. 2011.PubMed/NCBI
20	Yaligar J, Thakur SB, Bokacheva L, et al: Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomed. 25:113–122. 2012. View Article : Google Scholar : PubMed/NCBI
21	Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
22	Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 8:705–713. 2008. View Article : Google Scholar : PubMed/NCBI
23	Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1 dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:3387–3394. 2002.PubMed/NCBI
24	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
25	Williams KJ, Telfer BA, Xenaki D, et al: Enhanced response to radiotherapy in tumours deficient in the function of hypoxia inducible factor-1. Radiother Oncol. 75:89–98. 2005. View Article : Google Scholar : PubMed/NCBI
26	Masaki H, Okano Y and Sakurai H: Generation of active oxygen species from advanced glycation end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damaging. Biochim Biophys Acta. 1428:45–56. 1999. View Article : Google Scholar : PubMed/NCBI
27	Jagetia GC, Shetty PC and Vidyasagar MS: Inhibition of radiation-induced DNA damage by jamun, Syzygium cumini, in the cultured splenocytes of mice exposed to different doses of γ-radiation. Integr Cancer Ther. 11:141–153. 2012. View Article : Google Scholar : PubMed/NCBI
28	Sattler UG and Mueller-Klieser W: The anti-oxidant capacity of tumour glycolysis. Int J Radiat Biol. 85:963–971. 2009. View Article : Google Scholar : PubMed/NCBI
29	Sattler UG, Meyer SS, Quennet V, et al: Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol. 94:102–109. 2010. View Article : Google Scholar : PubMed/NCBI
30	Quennet V, Yaromina A, Zips D, et al: Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 81:130–135. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hirschhaeuser F, Sattler UG and Mueller-Klieser W: Lactate: a metabolic key player in cancer. Cancer Res. 71:6921–6925. 2011. View Article : Google Scholar : PubMed/NCBI
32	Kwasiborski PJ, Kowalczyk P, Mrówka P, et al: Selected, biochemical markers of hypoxia. Przegl Lek. 69:115–119. 2012.(In Polish). PubMed/NCBI
33	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
34	Jain RK: Normalization of tumor vasculature: An emerging concept of anti-angiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
35	Wen QL, Meng MB, Yang B, et al: Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci. 100:1510–1519. 2009. View Article : Google Scholar : PubMed/NCBI
36	Du H, Ge W, Li C, Zhao Z, Xu X and Yang F: Effects of rh-endostar in combination with radiotherapy on rats with lung cancer. Zhongguo Fei Ai Za Zhi. 13:386–390. 2010.(In Chinese). PubMed/NCBI
37	Xu M, Huang H, Xiong Y, Peng B, et al: Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature. Oncol Lett. 8:291–294. 2014.PubMed/NCBI
38	Huang G and Chen L: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 136:1201–1211. 2010. View Article : Google Scholar : PubMed/NCBI
39	Peng F, Xu Z, Wang J, et al: Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 7:e346462012. View Article : Google Scholar : PubMed/NCBI